VolitionRx FY2024 EPS Estimate Raised by Zacks Small Cap

VolitionRx Limited (NYSE:VNRX - Free Report) - Zacks Small Cap lifted their FY2024 earnings estimates for shares of VolitionRx in a research note issued on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now anticipates that the company will post earnings of ($0.28) per share for the year, up from their prior forecast of ($0.29). The consensus estimate for VolitionRx's current full-year earnings is ($0.31) per share. Zacks Small Cap also issued estimates for VolitionRx's Q4 2024 earnings at ($0.06) EPS.

VNRX has been the subject of a number of other reports. Benchmark restated a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com initiated coverage on shares of VolitionRx in a research report on Friday. They issued a "sell" rating for the company.

VolitionRx Trading Down 6.2 %

Shares of VNRX traded down $0.04 during mid-day trading on Monday, reaching $0.59. 78,888 shares of the stock traded hands, compared to its average volume of 164,995. The firm has a fifty day moving average price of $0.69 and a 200 day moving average price of $0.67. The company has a market cap of $54.68 million, a price-to-earnings ratio of -1.63 and a beta of 1.17. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its holdings in VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company's stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. Institutional investors own 8.09% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.